Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced that it has begun enrolling patients in a multicenter pediatric clinical study designed to assess the efficacy of EpiCeram(R) compared to Cutivate(R), a commonly prescribed mid-strength steroid, in patients with moderate-to-severe atopic dermatitis (eczema). The Company expects to report results of this trial in the fourth quarter of 2006.
